Background Neurocysticercosis, infection of the brain with larvae of Taenia solium (pork tapeworm), is one of several forms of human cysticercosis caused by this organism. We investigated the role of albendazole and praziquantel in the treatment of patients with parenchymal neurocysticercosis by performing a meta-analysis of comparative trials of their effectiveness and safety. Methods and Principal Findings We performed a search in the PubMed database, Cochrane Database of Controlled Trials, and in references of relevant articles. Six studies were included in the meta-analysis. Albendazole was associated with better control of seizures than praziquantel in the pooled data analysis, when the generic inverse variance method was used to combine the incidence of seizure control in the included trials (patients without seizures/[patients×years at risk]) (156 patients in 4 studies, point effect estimate [incidence rate ratio] = 4.94, 95% confidence interval 2.45–9.98). In addition, albendazole was associated with better effectiveness than praziquantel in the total disappearance of cysts (335 patients in 6 studies, random effects model, OR = 2.30, 95% CI 1.06–5.00). There was no difference between albendazole and praziquantel in reduction of cysts, proportion of patients with adverse events, and development of intracranial hypertension due to the administered therapy. Conclusions A critical review of the available data from comparative trials suggests that albendazole is more effective than praziquantel regarding clinically important outcomes in patients with neurocysticercosis. Nevertheless, given the relative scarcity of trials, more comparative interventional studies—especially randomized controlled trials—are required to draw a safe conclusion about the best regimen for the treatment of patients with parenchymal neurocysticercosis.
References
[1]
Hawk MW, Shahlaie K, Kim KD, Theis JH (2005) Neurocysticercosis: a review. Surg Neurol 63: 123–132. doi: 10.1016/j.surneu.2004.02.033
[2]
Willingham AL III, Engels D (2006) Control of Taenia solium cysticercosis/taeniosis. Adv Parasitol 61: 509–566. doi: 10.1016/S0065-308X(05)61012-3
[3]
Kraft R (2007) Cysticercosis: an emerging parasitic disease. Am Fam Physician 76: 91–96.
[4]
Shandera WX, Kass JS (2006) Neurocysticercosis: current knowledge and advances. Curr Neurol Neurosci Rep 6: 453–459. doi: 10.1007/s11910-006-0046-3
[5]
Sotelo J (2004) Neurocysticercosis–is the elimination of parasites beneficial? N Engl J Med 350: 280–282. doi: 10.1056/NEJMe038218
[6]
Del Brutto OH, Roos KL, Coffey CS, Garcia HH (2006) Meta-analysis: Cysticidal drugs for neurocysticercosis: albendazole and praziquantel. Ann Intern Med 145: 43–51. doi: 10.7326/0003-4819-145-1-200607040-00009
[7]
Noble JH Jr. (2006) Meta-analysis: Methods, strengths, weaknesses, and political uses. J Lab Clin Med 147: 7–20. doi: 10.1016/j.lab.2005.08.006
[8]
Khan KS, Daya S, Jadad A (1996) The importance of quality of primary studies in producing unbiased systematic reviews. Arch Intern Med 156: 661–666. doi: 10.1001/archinte.156.6.661
[9]
Moher D, Jadad AR, Tugwell P (1996) Assessing the quality of randomized controlled trials. Current issues and future directions. Int J Technol Assess Health Care 12: 195–208. doi: 10.1017/S0266462300009570
[10]
Higgins JP, Thompson SG (2004) Controlling the risk of spurious findings from meta-regression. Stat Med 23: 1663–1682. doi: 10.1002/sim.1752
[11]
Egger M, Davey SG, Schneider M, Minder C (1997) Bias in meta-analysis detected by a simple, graphical test. BMJ 315: 629–634. doi: 10.1136/bmj.315.7109.629
[12]
Mantel N, Haenszel W (1959) Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst 22: 719–748.
[13]
DerSimonian R, Laird N (1986) Meta-analysis in clinical trials. Control Clin Trials 7: 177–188. doi: 10.1016/0197-2456(86)90046-2
[14]
Del Brutto OH, Campos X, Sanchez J, Mosquera A (1999) Single-day praziquantel versus 1-week albendazole for neurocysticercosis. Neurology 52: 1079–1081. doi: 10.1212/WNL.52.5.1079
[15]
Carpio A, Santillan F, Leon P, Flores C, Hauser WA (1995) Is the course of neurocysticercosis modified by treatment with antihelminthic agents? Arch Intern Med 155: 1982–1988. doi: 10.1001/archinte.155.18.1982
[16]
Medina MT, Genton P, Montoya MC, Cordova S, Dravet C, et al. (1993) Effect of anticysticercal treatment on the prognosis of epilepsy in neurocysticercosis: a pilot trial. Epilepsia 34: 1024–1027. doi: 10.1111/j.1528-1157.1993.tb02128.x
[17]
Takayanagui OM, Jardim E (1992) Therapy for neurocysticercosis. Comparison between albendazole and praziquantel. Arch Neurol 49: 290–294. doi: 10.1001/archneur.1992.00530270106026
[18]
Cruz M, Cruz I, Horton J (1991) Albendazole versus praziquantel in the treatment of cerebral cysticercosis: clinical evaluation. Trans R Soc Trop Med Hyg 85: 244–247. doi: 10.1016/0035-9203(91)90041-V
[19]
Sotelo J, del Brutto OH, Penagos P, et al. (1990) Comparison of therapeutic regimen of anticysticercal drugs for parenchymal brain cysticercosis. J Neurol 237: 69–72. doi: 10.1007/BF00314663
[20]
Garcia HH, Gilman RH, Horton J, et al. (1997) Albendazole therapy for neurocysticercosis: a prospective double-blind trial comparing 7 versus 14 days of treatment. Cysticercosis Working Group in Peru. Neurology 48: 1421–1427. doi: 10.1212/WNL.48.5.1421
[21]
Bittencourt PR, Gracia CM, Gorz AM, Mazer S, Oliveira TV (1990) High-dose praziquantel for neurocysticercosis: efficacy and tolerability. Eur Neurol 30: 229–234. doi: 10.1159/000117352
[22]
Corona T, Lugo R, Medina R, Sotelo J (1996) Single-day praziquantel therapy for neurocysticercosis. N Engl J Med 334: 125. doi: 10.1056/NEJM199601113340216
[23]
Sotelo J, Escobedo F, Rodriguez-Carbajal J, Torres B, Rubio-Donnadieu F (1984) Therapy of parenchymal brain cysticercosis with praziquantel. N Engl J Med 310: 1001–1007. doi: 10.1056/NEJM198404193101601
[24]
White AC Jr. (1997) Neurocysticercosis: a major cause of neurological disease worldwide. Clin Infect Dis 24: 101–113. doi: 10.1093/clinids/24.2.101
[25]
Garcia HH, Evans CA, Nash TE, et al. (2002) Current consensus guidelines for treatment of neurocysticercosis. Clin Microbiol Rev 15: 747–756. doi: 10.1128/CMR.15.4.747-756.2002
[26]
Vazquez ML, Jung H, Sotelo J (1987) Plasma levels of praziquantel decrease when dexamethasone is given simultaneously. Neurology 37: 1561–1562. doi: 10.1212/WNL.37.9.1561
[27]
Bittencourt PR, Gracia CM, Martins R, Fernandes AG, Diekmann HW, et al. (1992) Phenytoin and carbamazepine decreased oral bioavailability of praziquantel. Neurology 42: 492–496. doi: 10.1212/WNL.42.3.492
[28]
Dachman WD, Adubofour KO, Bikin DS, Johnson CH, Mullin PD, et al. (1994) Cimetidine-induced rise in praziquantel levels in a patient with neurocysticercosis being treated with anticonvulsants. J Infect Dis 169: 689–691. doi: 10.1093/infdis/169.3.689
[29]
Jung H, Hurtado M, Medina MT, Sanchez M, Sotelo J (1990) Dexamethasone increases plasma levels of albendazole. J Neurol 237: 279–280. doi: 10.1007/BF00314741
[30]
Takayanagui OM, Lanchote VL, Marques MP, Bonato PS (1997) Therapy for neurocysticercosis: pharmacokinetic interaction of albendazole sulfoxide with dexamethasone. Ther Drug Monit 19: 51–55. doi: 10.1097/00007691-199702000-00009
[31]
Rangel R, Torres B, Del BO, Sotelo J (1987) Cysticercotic encephalitis: a severe form in young females. Am J Trop Med Hyg 36: 387–392.
[32]
Garg RK (1997) Drug treatment of neurocysticercosis. Natl Med J India 10: 173–177.
[33]
Miller B, Grinnell V, Goldberg MA, Heiner D (1983) Spontaneous radiographic disappearance of cerebral cysticercosis: three cases. Neurology 33: 1377–1379. doi: 10.1212/WNL.33.10.1377
